First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors

CBP-1008 - Coherent Biopharma

https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal_2/presentation

N. Li1; J. Gong2; J. Zhang3; D. Liu2; Y. Chen4; Y. Zhang5; Y. Huang6; J. Wang7; J. Tang7; G. Li8; Y. Wang9; J. Wu10; S. Luo11; G. Lou12; W. Duan13; R. Huang14; M. Xu15; X. Hu16; L. Wu1; L. Shen2

Jul 19, 2024